Key result
Intracoronary prourokinase yields ~28% higher complete ST-segment resolution during primary PCI for STEMI.
Why the study?
Persistent microvascular obstruction and incomplete myocardial reperfusion remain significant challenges in STEMI despite timely primary PCI, and the effect of low-dose intracoronary prourokinase is uncertain.
Does adjunct intracoronary low-dose prourokinase improve myocardial reperfusion and clinical outcomes compared to control in adults with STEMI undergoing primary PCI?
Meta-Analysis (n=1,328)
Randomized
Does adjunct intracoronary low-dose prourokinase improve myocardial reperfusion and clinical outcomes compared to control in adults with STEMI undergoing primary PCI?
Adjunct intracoronary low-dose prourokinase improves angiographic and electrocardiographic markers of myocardial reperfusion during primary PCI for STEMI, though adequately powered contemporary trials are required to confirm clinical outcome benefits.
Answers are grounded in this paper and cite their sources.
Improves ST-segment resolution in STEMI primary PCI; extends surrogate evidence from RCTs but leaves clinical outcomes and safety open.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Reartes et al. (2026) conducted a meta-analysis in ST-elevation myocardial infarction (STEMI) (n=1,328). Intracoronary low-dose prourokinase vs. Control (no intracoronary fibrinolytic/placebo/saline) was evaluated on Complete ST-segment resolution (RR 1.28, 95% CI 1.12-1.46, p=<0.001). Adjunct intracoronary low-dose prourokinase improved complete ST-segment resolution compared to control in adults with STEMI undergoing primary PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: